JP2010502588A - 特定のエンドセリン受容体アンタゴニストとpde5阻害剤を含む治療用組成物 - Google Patents
特定のエンドセリン受容体アンタゴニストとpde5阻害剤を含む治療用組成物 Download PDFInfo
- Publication number
- JP2010502588A JP2010502588A JP2009526239A JP2009526239A JP2010502588A JP 2010502588 A JP2010502588 A JP 2010502588A JP 2009526239 A JP2009526239 A JP 2009526239A JP 2009526239 A JP2009526239 A JP 2009526239A JP 2010502588 A JP2010502588 A JP 2010502588A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- inhibitory properties
- formula
- pde5 inhibitory
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title description 7
- 229940118365 Endothelin receptor antagonist Drugs 0.000 title description 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title description 3
- 239000002308 endothelin receptor antagonist Substances 0.000 title description 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 85
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims abstract description 40
- 101150098694 PDE5A gene Proteins 0.000 claims abstract description 40
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims abstract description 40
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 34
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 229960000835 tadalafil Drugs 0.000 claims abstract description 18
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims abstract description 18
- 229960003310 sildenafil Drugs 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 206010020772 Hypertension Diseases 0.000 claims abstract description 11
- 206010047139 Vasoconstriction Diseases 0.000 claims abstract description 10
- 208000002815 pulmonary hypertension Diseases 0.000 claims abstract description 10
- 230000025033 vasoconstriction Effects 0.000 claims abstract description 10
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 7
- 206010019280 Heart failures Diseases 0.000 claims abstract description 7
- 201000001881 impotence Diseases 0.000 claims abstract description 7
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 6
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000438 udenafil Drugs 0.000 claims abstract description 6
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002381 vardenafil Drugs 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N CCCNS(Nc1c(-c(cc2)ccc2Br)c(OCCOc(nc2)ncc2Br)ncn1)(=O)=O Chemical compound CCCNS(Nc1c(-c(cc2)ccc2Br)c(OCCOc(nc2)ncc2Br)ncn1)(=O)=O JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 description 1
- WOXKDUGGOYFFRN-IIBYNOLFSA-N CN(CC(N([C@@H]1Cc2c3[nH]c4c2cccc4)[C@@H]3c(cc2)cc3c2OCO3)=O)C1=O Chemical compound CN(CC(N([C@@H]1Cc2c3[nH]c4c2cccc4)[C@@H]3c(cc2)cc3c2OCO3)=O)C1=O WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
PDE-5阻害剤は、以下の特許文献中で特に記載されている。
* 特許文献2には、PDE-5阻害剤としてのピラゾロピリミジノン誘導体およびとりわけシルデナフィルの記述に加えて、とりわけ高血圧および心不全のための同薬剤の使用が記述されている。特許文献3には、肺高血圧症のためのとりわけシルデナフィルが記述されている。
* 特許文献4には、とりわけバルデナフィルの記述に加えて、とりわけ高血圧、狭心症および勃起障害のための同薬剤の使用が記述されている。
* 特許文献5には、とりわけタダラフィルの記述に加えて、とりわけ高血圧、肺高血圧症、狭心症およびうっ血性心不全のための同薬剤の使用が記述されている。
* 特許文献6には、とりわけウデナフィル、およびインポテンスのためのその使用が記述されている。
この後記述される実験方法は、本発明化合物の薬理学的特性を示すために使用できる。
ダール食塩感受性(ダール-S)は、ハーラン(Harlan )社(オランダ)から購入した。ラットは、環境順化期間の間はグループで収容し、遠隔測定装置の移植後は単独で収容した。動物はすべて同一の条件下で飼育され、通常のラット用ペレット餌および水に自由に接近させた。ダール食塩感受性ラットは、食塩摂取に対する暴露に際してのみ高血圧を発症する。それらのラットに高食塩(8%)餌(ピュリナ(Purina)社シリーズ5500)を投与した。食塩投与の開始5週間後に、遠隔測定システムを、2.5%イソフルラン(70%O2+30%N2O中)の吸入による麻酔下で移植した。無菌状態下で、圧力無線周波数発信機を腹膜腔の中へ移植し、検出カテーテルを下行大動脈中に挿入して腎動脈分岐のわずかに下まで上流に向かって進めた。発信機を腹部の筋肉組織に縫合し、皮膚を閉じた。レシーバープラットフォームにより、無線信号は専用パソコン(コンパック(Compaq)社、デスクプロ(deskpro))に送られるデジタル化入力へと変換された。動脈圧測定は周囲圧力参照からの入力を使用することによって較正された。遠隔測定ユニットはデーター・サイエンス(Data Sciences)社(セント・ポール、ミネソタ、アメリカ)から入手した。遠隔測定システム移植の少なくとも2週間後に、化合物を投与した。式(I)の化合物およびPDE5阻害特性を有する化合物を、5%アラビアゴム中で調製し、強制経口投与によって投与した。式(I)の化合物、PDE5阻害特性を有する化合物、およびそれらの組合せの血圧に対する急性効果は、経口投与後72時間まで5分の間隔でのデーター回収よって測定された。一時間ごとの血圧の平均値を各ラットについて計算した。各ラットは、薬物投与前の最後の24時間の血圧データーを使用して、自身の対照とした。2本の曲線(対照期間の血圧および治療期間の血圧)をともにプロットし、0〜72時間の曲線間面積(ABC)を計算した。ABCが多いほど、試験品の血圧低下効果は強い。
ダール-Sラットを自然発症高血圧ラット(SHR)で置き換えたこと、およびSHRラットに食塩入り食餌を与えないこと以外は、ダール食塩感受性ラットモデルと同一のプロトコールを使用した。SHRラットはハーラン社(オランダ)から購入した。
試験化合物のPDE5活性に対する阻害度を推定するために、以下の試験を行なう。ホスホジエステラーゼ-5酵素(PDE 5)はヒト海綿体組織から分離される。約3gのこの組織を、12mlのヘペス・バッファー(20mMヘペス、250mMショ糖、1mM EDTA、1mM PMSF、pH 7.2)により4℃でホモジナイズする。溶液を2層のガーゼにより濾過し、60分間4℃で遠心分離(100,000×g)する。上清を0.2μm濾紙により濾過し、0〜500mM NaClの濃度勾配でHPLC(モノQ陰イオン交換カラム)によって分離し、PDEアイソザイムを溶出する。P PDE5画分を分離するために以下のプロセスによって各カラム画分に対して酵素活性を測定し、試験化合物のPDE5阻害はPDE5画分を使用して測定する。1.5mlのチューブに、100μlの反応混合物(15mMトリス-HCl、5mM MgCl2、0.5mg/mlのBSA、pH7.4)および適切な量の試験化合物画分を追加し、試験化合物および混合物をよく混合する。この溶液に3H-cAMPまたは3H-cGMP(500nM、2μCi/ml)を追加し、混合物を30℃のインキュベータ中で約1時間反応させ、約45秒〜2分間煮湯の中へチューブを入れて反応を終了させる。次にチューブを氷浴中で約5分間冷やす。このチューブに蛇毒(1mg/ml、100μl)または5-ヌクレオチダーゼ(0.1ユニット/チューブ)を追加し、混合物をインキュベータ中で10分間37℃で反応させ、氷浴中で冷やす。0.5N HCl、水、0.5N NaOH、水、0.5N HClおよび水の順序で既に洗浄し、pH5に調整した陰イオン交換樹脂(バイオ・ラッド樹脂、AG1-X2、200〜400メッシュ)に、樹脂の3倍の体積のメタノールを加える。次に1mlの前処理した樹脂を、ボルテックスにより撹拌しながら各チューブの中へ分注する。混合物は時々ボルテックスにより撹拌しながら15分間4℃で放置し、約5分間遠心分離し(10,000rpm)、樹脂を沈殿させる。上清(700μl)を液体シンチレーションバイアルに移し、10mlのシンチレーションカクテルと混合する。それを一晩放置することによって溶液を安定化した後に、チューブの放射能をβ-カウンターによって測定する。試験化合物が、1μM以下のIC50を有するならば、この特許出願のためのPDE5阻害特性を有すると見なされる。試験化合物が1μMよりも高いIC50を有するならば、この特許出願のためのPDE5阻害特性を有していないと見なされる。
Claims (12)
- 前記PDE5阻害特性を有する化合物が、シルデナフィル、バルデナフィル、タダラフィルおよびウデナフィルから選択される、請求項1に記載の生成物。
- 前記PDE5阻害特性を有する化合物がタダラフィルである、請求項2に記載の生成物。
- 前記PDE5阻害特性を有する化合物がシルデナフィルである、請求項2に記載の生成物。
- 前記血管収縮が関与する疾患が、高血圧、肺高血圧症、糖尿病性動脈症、心不全、勃起障害および狭心症から選択される、請求項1に記載の生成物。
- PDE5阻害特性を有する少なくとも1つの化合物またはその薬学的に許容される塩に加えて、少なくとも1つの賦形剤との組合せにおいて、有効成分として請求項1に記載される式(I)の化合物または式(I)の該化合物の薬学的に許容される塩を含む、医薬組成物。
- 前記PDE5阻害特性を有する化合物が、シルデナフィル、バルデナフィル、タダラフィルおよびウデナフィルから選択される、請求項6に記載の医薬組成物。
- 前記PDE5阻害特性を有する化合物がタダラフィルである、請求項7に記載の医薬組成物。
- 前記PDE5阻害特性を有する化合物がシルデナフィルである、請求項7に記載の医薬組成物。
- 血管収縮が関与する疾患の治療を意図した医薬品の製造のための、PDE5阻害特性を有する少なくとも1つの化合物またはその薬学的に許容される塩との組合せにおける、請求項1に記載される式(I)の化合物または式(I)の該化合物の薬学的に許容される塩の使用。
- 前記PDE5阻害特性を有する化合物が、シルデナフィル、バルデナフィル、タダラフィルおよびウデナフィルから選択される、請求項10に記載の使用。
- 治療が意図される前記疾患が高血圧および肺高血圧症から選択される、請求項10に記載の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2006052999 | 2006-08-29 | ||
IBPCT/IB2006/052999 | 2006-08-29 | ||
IBPCT/IB2006/053857 | 2006-10-19 | ||
IB2006053857 | 2006-10-19 | ||
PCT/IB2007/053448 WO2008026156A2 (en) | 2006-08-29 | 2007-08-28 | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010502588A true JP2010502588A (ja) | 2010-01-28 |
JP5208113B2 JP5208113B2 (ja) | 2013-06-12 |
Family
ID=38954615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009526239A Active JP5208113B2 (ja) | 2006-08-29 | 2007-08-28 | 特定のエンドセリン受容体アンタゴニストとpde5阻害剤を含む治療用組成物 |
Country Status (27)
Country | Link |
---|---|
US (8) | US8268847B2 (ja) |
EP (1) | EP2059246B1 (ja) |
JP (1) | JP5208113B2 (ja) |
KR (1) | KR101473022B1 (ja) |
CN (1) | CN101511365B (ja) |
AR (1) | AR062501A1 (ja) |
AU (1) | AU2007290099B2 (ja) |
BR (1) | BRPI0715698B8 (ja) |
CA (1) | CA2659770C (ja) |
CL (1) | CL2007002494A1 (ja) |
CY (1) | CY1114735T1 (ja) |
DK (1) | DK2059246T3 (ja) |
ES (1) | ES2438792T3 (ja) |
HK (1) | HK1133597A1 (ja) |
HR (1) | HRP20131233T1 (ja) |
IL (1) | IL197235A (ja) |
MA (1) | MA30704B1 (ja) |
MX (1) | MX2009002057A (ja) |
MY (1) | MY154591A (ja) |
NO (1) | NO342554B1 (ja) |
NZ (1) | NZ575702A (ja) |
PL (1) | PL2059246T3 (ja) |
PT (1) | PT2059246E (ja) |
RU (1) | RU2462249C2 (ja) |
SI (1) | SI2059246T1 (ja) |
TW (1) | TWI388556B (ja) |
WO (1) | WO2008026156A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006290309B2 (en) | 2005-09-12 | 2012-04-05 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
CN101939001B (zh) * | 2008-02-20 | 2012-06-20 | 埃科特莱茵药品有限公司 | 用于治疗卵巢癌的含有紫杉醇的组合 |
PL2315587T3 (pl) | 2008-08-13 | 2018-03-30 | Actelion Pharmaceuticals Ltd. | Kompozycje terapeutyczne zawierające macitentan |
TWI462739B (zh) * | 2010-11-02 | 2014-12-01 | Univ Kaohsiung Medical | Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途 |
CN102949395A (zh) * | 2011-09-22 | 2013-03-06 | 荆志成 | 盐酸伐地那非片在制备治疗肺动脉高压药物中的应用 |
CN102839165B (zh) * | 2012-09-26 | 2014-12-10 | 金普诺安生物科技(苏州)有限公司 | 基因突变型重组蛋白酶k及其工业化生产方法 |
WO2014198178A1 (zh) * | 2013-06-14 | 2014-12-18 | 杭州普晒医药科技有限公司 | 马西替坦晶体及其制备方法、其药物组合物和用途 |
KR20190030805A (ko) | 2017-09-14 | 2019-03-25 | 경상대학교산학협력단 | 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법 |
AU2019410727A1 (en) * | 2018-12-21 | 2021-08-12 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004517855A (ja) * | 2000-12-18 | 2004-06-17 | アクテリオン ファマシューティカルズ リミテッド | 新規なスルファミド類 |
WO2006026395A1 (en) * | 2004-08-26 | 2006-03-09 | Encysive Pharmaceuticals | Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2801584A1 (de) | 1978-01-14 | 1979-07-19 | Bayer Ag | Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
US5589006A (en) * | 1993-11-30 | 1996-12-31 | Canon Kabushiki Kaisha | Solar battery module and passive solar system using same |
IL111959A (en) | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
WO1996016963A1 (de) | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
TW313568B (ja) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US5739333A (en) | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
ES2156305T3 (es) | 1995-12-20 | 2001-06-16 | Yamanouchi Pharma Co Ltd | Derivados de ariletenosulfonamida y composiciones de farmacos que los contienen. |
DE19881732D2 (de) | 1997-11-12 | 2000-08-24 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren |
US6087368A (en) * | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
TWI284642B (en) | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
HUP0201402A3 (en) | 1999-09-03 | 2003-12-29 | Actelion Pharmaceuticals Ltd | Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them |
TW200400821A (en) | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
BR0016241A (pt) | 1999-12-22 | 2002-11-12 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas |
WO2001081335A1 (en) | 2000-04-20 | 2001-11-01 | Actelion Pharmaceuticals Ltd | Pyrimidine-sulfonamides having endothelin-antagonist activity |
AU2001265871A1 (en) | 2000-04-25 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
US7094081B1 (en) | 2005-03-24 | 2006-08-22 | Delphi Technologies, Inc. | Electrical connector assembly |
AU2006290309B2 (en) | 2005-09-12 | 2012-04-05 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
CA2641952C (en) | 2006-04-13 | 2011-02-01 | Actelion Pharmaceuticals Ltd | Treatment of early stage idiopathic pulmonary fibrosis |
-
2007
- 2007-08-23 AR ARP070103749A patent/AR062501A1/es not_active Application Discontinuation
- 2007-08-27 CL CL200702494A patent/CL2007002494A1/es unknown
- 2007-08-28 PT PT78261674T patent/PT2059246E/pt unknown
- 2007-08-28 NZ NZ575702A patent/NZ575702A/en unknown
- 2007-08-28 ES ES07826167.4T patent/ES2438792T3/es active Active
- 2007-08-28 AU AU2007290099A patent/AU2007290099B2/en active Active
- 2007-08-28 MY MYPI20090795A patent/MY154591A/en unknown
- 2007-08-28 RU RU2009111378/15A patent/RU2462249C2/ru active
- 2007-08-28 MX MX2009002057A patent/MX2009002057A/es active IP Right Grant
- 2007-08-28 WO PCT/IB2007/053448 patent/WO2008026156A2/en active Application Filing
- 2007-08-28 EP EP07826167.4A patent/EP2059246B1/en active Active
- 2007-08-28 DK DK07826167.4T patent/DK2059246T3/da active
- 2007-08-28 PL PL07826167T patent/PL2059246T3/pl unknown
- 2007-08-28 KR KR1020097005029A patent/KR101473022B1/ko active IP Right Grant
- 2007-08-28 TW TW096131928A patent/TWI388556B/zh active
- 2007-08-28 BR BRPI0715698A patent/BRPI0715698B8/pt active IP Right Grant
- 2007-08-28 SI SI200731367T patent/SI2059246T1/sl unknown
- 2007-08-28 JP JP2009526239A patent/JP5208113B2/ja active Active
- 2007-08-28 CA CA2659770A patent/CA2659770C/en active Active
- 2007-08-28 US US12/439,290 patent/US8268847B2/en active Active
- 2007-08-28 CN CN2007800321481A patent/CN101511365B/zh active Active
-
2009
- 2009-02-25 IL IL197235A patent/IL197235A/en active IP Right Grant
- 2009-03-06 MA MA31695A patent/MA30704B1/fr unknown
- 2009-03-26 NO NO20091254A patent/NO342554B1/no unknown
-
2010
- 2010-02-11 HK HK10101538.5A patent/HK1133597A1/xx unknown
-
2012
- 2012-09-05 US US13/604,148 patent/US20130210830A9/en not_active Abandoned
-
2013
- 2013-12-27 CY CY20131101163T patent/CY1114735T1/el unknown
- 2013-12-30 HR HRP20131233TT patent/HRP20131233T1/hr unknown
-
2014
- 2014-01-23 US US14/162,280 patent/US20140148460A1/en not_active Abandoned
-
2018
- 2018-01-26 US US15/881,060 patent/US20180147205A1/en not_active Abandoned
- 2018-11-16 US US16/193,859 patent/US20190083494A1/en not_active Abandoned
-
2019
- 2019-10-11 US US16/599,582 patent/US20200038401A1/en not_active Abandoned
-
2020
- 2020-07-30 US US16/942,895 patent/US20200352944A1/en not_active Abandoned
-
2021
- 2021-02-25 US US17/185,238 patent/US20210177849A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004517855A (ja) * | 2000-12-18 | 2004-06-17 | アクテリオン ファマシューティカルズ リミテッド | 新規なスルファミド類 |
WO2006026395A1 (en) * | 2004-08-26 | 2006-03-09 | Encysive Pharmaceuticals | Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5208113B2 (ja) | 特定のエンドセリン受容体アンタゴニストとpde5阻害剤を含む治療用組成物 | |
ZA200509311B (en) | Method of improved diuresis in individuals with impaired renal function | |
US9700565B2 (en) | Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias | |
TW200423932A (en) | Combination of a PDE IV inhibitor and a TNF-alpha antagonist | |
JP2003513888A (ja) | 神経疾患治療用医薬品 | |
US20140088054A1 (en) | Method For Treating Erectile Dysfunction | |
JP2010222347A (ja) | Pde5阻害剤及びカルニチンを含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100217 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100217 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100812 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130121 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130213 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130219 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160301 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5208113 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |